Brief: Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy
28/03/2026 11:13
March 28 (Reuters) - Bristol-Myers Squibb Co BMY.N: BRISTOL-MYERS SQUIBB: OPEN LABEL OUTPATIENT SWITCH STUDY DEMONSTRATES SYMPTOM STABILITY DURING TRANSITION FROM ORAL ATYPICAL ANTIPSYCHOTICS TO COBENFY Source text: ID:nBwyC8L0a Further company coverage: BMY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC